Source:http://linkedlifedata.com/resource/pubmed/id/11468154
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2001-7-24
|
pubmed:abstractText |
Current therapeutic options for myeloid metaplasia with myelofibrosis (MMM) are limited. A pilot study was conducted of autologous peripheral blood stem cell (PBSC) collection in 27, followed by transplantation in 21 patients with MMM. The median age was 59 (range 45-75) years. PBSCs were mobilized at steady state (n = 2), after granulocyte colony-stimulating factor (G-CSF) alone (n = 17), or after anthracycline-cytarabine induction plus G-CSF (n = 8). A median of 11.6 x 10(6) (range 0 to 410 x 10(6)) CD34(+) cells per kilogram were collected. Twenty-one patients then underwent myeloablation with oral busulfan (16 mg/kg) and PBSC transplantation. The median times to neutrophil and platelet recovery after transplantation were 21 (range 10-96) and 21 (range, 13 to > or = 246) days, respectively. Five patients received back-up PBSC infusion because of delayed neutrophil or platelet recovery. The median follow-up is 390 (range 70-1623) days after transplantation, and the 2-year actuarial survival is 61%. After transplantion, 6 patients died: 3 of nonrelapse causes (1 within 100 days of PBSC infusion) and 3 of disease progression. Erythroid response (hemoglobin > or = 100 g/L [10 gm/dL] without transfusion for > or = 8 weeks) occurred in 10 of 17 anemic patients. Four of 8 patients with a platelet count less than 100 x 10(9)/L (100 000/microL) responded with a durable platelet count more than 100 x 10(9)/L (100 000/microL). Symptomatic splenomegaly improved in 7 of 10 patients. It is concluded that (1) PBSC collection was feasible and stable engraftment occurred after transplantation in most patients with MMM, (2) myeloablation with busulfan was associated with acceptable toxicity, (3) a significant proportion of patients derived clinical benefit after treatment, and (4) further investigation of this novel approach is warranted. (Blood. 2001;98:586-593)
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:AndersonJ EJE,
pubmed-author:AppelbaumF RFR,
pubmed-author:CallanderNN,
pubmed-author:ChaunceyTT,
pubmed-author:CraigFF,
pubmed-author:DeegH JHJ,
pubmed-author:FreytesCC,
pubmed-author:GazittYY,
pubmed-author:GuardiolaPP,
pubmed-author:HolmbergLL,
pubmed-author:RazvillasBB,
pubmed-author:TefferiAA
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
98
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
586-93
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:11468154-Aged,
pubmed-meshheading:11468154-Busulfan,
pubmed-meshheading:11468154-Follow-Up Studies,
pubmed-meshheading:11468154-Graft Survival,
pubmed-meshheading:11468154-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11468154-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11468154-Humans,
pubmed-meshheading:11468154-Middle Aged,
pubmed-meshheading:11468154-Pilot Projects,
pubmed-meshheading:11468154-Primary Myelofibrosis,
pubmed-meshheading:11468154-Splenomegaly,
pubmed-meshheading:11468154-Survival Rate,
pubmed-meshheading:11468154-Transplantation, Autologous,
pubmed-meshheading:11468154-Transplantation Conditioning,
pubmed-meshheading:11468154-Treatment Outcome
|
pubmed:year |
2001
|
pubmed:articleTitle |
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.
|
pubmed:affiliation |
Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio, TX, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|